{"id":"https://openalex.org/W1970341069","doi":"https://doi.org/10.1159/000055397","title":"Herceptin\u00ae Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials","display_name":"Herceptin\u00ae Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials","alternate_titles":[],"publication_year":2001,"publication_date":"2001-10-26","ids":{"openalex":"https://openalex.org/W1970341069","doi":"https://doi.org/10.1159/000055397","mag":"1970341069","pmid":"https://pubmed.ncbi.nlm.nih.gov/11694783"},"language":"en","primary_location":{"id":"doi:10.1159/000055397","doi":"https://doi.org/10.1159/000055397","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000055397","pdf_url":null,"source":{"id":"https://openalex.org/S198727964","display_name":"Oncology","issn_l":"0030-2414","issn":["0030-2414","1423-0232"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1970341069"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Jos\u00e9 Baselga","raw_affiliation_strings":["Medical Oncology Service, Hospital General, Universitari Vall d'Hebron, Barcelona, Spain. baselga@hg.vhebron.es","Medical Oncology Service, Hospital General, Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Service, Hospital General, Universitari Vall d'Hebron, Barcelona, Spain. baselga@hg.vhebron.es","institution_ids":["https://openalex.org/I4210127641"]},{"raw_affiliation_string":"Medical Oncology Service, Hospital General, Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5004300577"],"corresponding_institution_ids":["https://openalex.org/I4210127641"],"apc_list":null,"apc_paid":null,"fwci":5.9351,"has_fulltext":false,"cited_by_count":197,"citation_normalized_percentile":{"value":0.96628576,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"61","issue":"Suppl. 2","first_page":"14","last_page":"21"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-her2-monoclonal-antibody","display_name":"anti-HER2 monoclonal antibody","score":0.9290000200271606},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7379999756813049},{"id":"https://openalex.org/keywords/her2-immunohistochemistry","display_name":"HER2 immunohistochemistry","score":0.7590000033378601},{"id":"https://openalex.org/keywords/her2-fluorescence-in-situ-hybridization","display_name":"HER2 fluorescence in situ hybridization","score":0.8920000195503235},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.6039999723434448},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9330000281333923},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5849999785423279}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8345790505409241},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7084490060806274},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7023870944976807},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6943775415420532},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.6928240656852722},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6849740147590637},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5295618176460266},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5275787115097046},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5238109827041626},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.4907187223434448},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48571333289146423},{"id":"https://openalex.org/C160798450","wikidata":"https://www.wikidata.org/wiki/Q4230870","display_name":"Concordance","level":2,"score":0.4649350345134735},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009363","descriptor_name":"Neoplasm Proteins","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012449","descriptor_name":"Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017404","descriptor_name":"In Situ Hybridization, Fluorescence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1159/000055397","doi":"https://doi.org/10.1159/000055397","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000055397","pdf_url":null,"source":{"id":"https://openalex.org/S198727964","display_name":"Oncology","issn_l":"0030-2414","issn":["0030-2414","1423-0232"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology","raw_type":"journal-article"},{"id":"pmid:11694783","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11694783","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W35533511","https://openalex.org/W1874305637","https://openalex.org/W1890809256","https://openalex.org/W1933350662","https://openalex.org/W1964896818","https://openalex.org/W1966823692","https://openalex.org/W1974129471","https://openalex.org/W1980184027","https://openalex.org/W1982093899","https://openalex.org/W1984274637","https://openalex.org/W2001627828","https://openalex.org/W2006174096","https://openalex.org/W2014053430","https://openalex.org/W2020124426","https://openalex.org/W2037769103","https://openalex.org/W2038173563","https://openalex.org/W2038863791","https://openalex.org/W2046180857","https://openalex.org/W2082117763","https://openalex.org/W2091738980","https://openalex.org/W2095156669","https://openalex.org/W2141393790","https://openalex.org/W2149051154","https://openalex.org/W2154027407","https://openalex.org/W2159363679","https://openalex.org/W2159459001","https://openalex.org/W2222638000","https://openalex.org/W2318605753","https://openalex.org/W2344444710"],"related_works":["https://openalex.org/W2351245776","https://openalex.org/W2129318515","https://openalex.org/W2136166098","https://openalex.org/W2034690275","https://openalex.org/W2157448426","https://openalex.org/W1969275840","https://openalex.org/W2349221809","https://openalex.org/W2077498864","https://openalex.org/W203485479"],"abstract_inverted_index":{"Large":[0],"pivotal":[1],"phase":[2],"II":[3],"and":[4,12,22,39,79,111,147,158,182,199,204],"III":[5],"clinical":[6,96,106,142],"trials":[7],"investigated":[8],"the":[9,15,101,109,123,152,162,202],"therapeutic":[10],"efficacy":[11,114],"safety":[13],"of":[14,77,103,136,175],"humanized":[16],"anti-HER2":[17],"monoclonal":[18],"antibody,":[19],"Herceptin,":[20],"alone":[21],"in":[23,29,51,63,67,92,108,117,126,131,144,161,169,201],"combination":[24,64],"with":[25,65,122,151],"standard":[26],"chemotherapy,":[27,66],"respectively,":[28],"HER2-positive":[30],"metastatic":[31,203],"breast":[32],"cancer.":[33],"Eligible":[34],"patients":[35,120,178],"were":[36,166],"HER2":[37,138,176],"2+":[38,177],"3+":[40,119,146],"overexpressors,":[41],"as":[42],"determined":[43],"by":[44],"immunohistochemistry":[45],"(IHC).":[46],"Herceptin":[47,56,62,104,164,197],"was":[48,115],"well":[49],"tolerated":[50],"both":[52,127],"trials.":[53,128],"Single-agent":[54],"second/third-line":[55],"produced":[57],"durable":[58],"tumor":[59],"responses.":[60],"First-line":[61],"particular":[68],"paclitaxel,":[69],"significantly":[70],"improved":[71],"time":[72,80],"to":[73,81,100,194],"disease":[74],"progression,":[75],"duration":[76],"response":[78],"treatment":[82],"failure.":[83],"Combination":[84],"therapy":[85],"also":[86],"provided":[87],"a":[88,173],"significant":[89],"25%":[90],"improvement":[91],"overall":[93,124],"survival.":[94],"These":[95],"benefits":[97],"have":[98],"led":[99],"approval":[102],"for":[105],"use":[107],"USA":[110],"elsewhere.":[112],"Greater":[113],"noted":[116],"IHC":[118,145,157],"compared":[121],"population":[125],"Retrospective":[129],"fluorescent":[130],"situ":[132],"hybridization":[133],"(FISH)":[134],"testing":[135],"patient-tumor":[137],"status":[139],"revealed":[140],"similar":[141],"outcomes":[143],"FISH-positive":[148,170],"patients,":[149],"consistent":[150],"reported":[153],"high":[154],"concordance":[155],"between":[156],"FISH.":[159],"Responses":[160],"single-agent":[163],"trial":[165],"seen":[167],"exclusively":[168],"patients.":[171],"Approximately":[172],"quarter":[174],"test":[179],"FISH":[180],"positive":[181],"may":[183],"therefore":[184],"benefit":[185],"from":[186],"therapy.":[187],"Numerous":[188],"studies":[189],"are":[190],"underway":[191],"or":[192],"planned":[193],"evaluate":[195],"other":[196],"combinations":[198],"regimens":[200],"adjuvant":[205],"settings.":[206]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1970341069","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":11},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
